Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Metastatic Colorectal Cancer
| Status: | Archived |
|---|---|
| Conditions: | Colorectal Cancer, Cancer, Cancer, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2009 |
| End Date: | July 2012 |
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors Followed by a Randomized Phase II Study of XELOX-A-Ev Compared to Capecitabine, Oxaliplatin, Bevacizumab (XELOX-A) in Subjects With Previously Untreated Metastatic Colorectal Cancer
The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard
treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in metastatic colon cancer.
We found this trial at
4
sites
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
Click here to add this to my saved trials
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials